title: Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): a case report.
abstract: The occurrence of radiation necrosis to the extravasation of therapeutic radionuclide-yttrium-90-ibritumomab tiuxetan-is described, as well as the subsequent steps taken to both address the occurrence and to prevent the re-occurrence of such an adverse event. Published reports on the extravasation of diagnostic and therapeutic radionuclides are reviewed, as are prevention and treatment protocols.
authors.affiliation: Nuclear Medicine, Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA 02215-5400, USA.
authors.forename: Gethin
authors.initials: G
authors.lastname: Williams
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Palmer
authors.forename: J Anthony
authors.initials: JA
authors.lastname: Parker
authors.forename: Robin
authors.initials: R
authors.lastname: Joyce
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005119:Extravasation of Diagnostic and Therapeutic Materials; D006801:Humans; D008297:Male; D008875:Middle Aged; D011832:Radiation Injuries / Q000209:etiology*; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods; D015021:Yttrium Radioisotopes / Q000009:adverse effects*
chemical_list: D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan